Allergy Therapeutics plc (LON:AGY - Get Free Report) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 10.23 and traded as low as GBX 10.11. Allergy Therapeutics shares last traded at GBX 10.59, with a volume of 390,663 shares changing hands.
Allergy Therapeutics Stock Performance
The firm has a fifty day moving average price of GBX 10.75 and a 200 day moving average price of GBX 10.23. The company has a debt-to-equity ratio of 629.58, a quick ratio of 1.48 and a current ratio of 1.13. The stock has a market cap of £670.49 million, a PE ratio of -10.92, a price-to-earnings-growth ratio of -30.70 and a beta of 0.83.
Allergy Therapeutics (LON:AGY - Get Free Report) last issued its earnings results on Tuesday, March 31st. The company reported GBX (0.38) earnings per share (EPS) for the quarter. The firm had revenue of GBX 3,628 million during the quarter. Allergy Therapeutics had a positive return on equity of 409.00% and a negative net margin of 85.46%. Research analysts forecast that Allergy Therapeutics plc will post -2.56 earnings per share for the current fiscal year.
About Allergy Therapeutics
(
Get Free Report)
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Allergy Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allergy Therapeutics wasn't on the list.
While Allergy Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
